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Aims: To investigate the efficacy and safety of alirocumab in participants with type 2 (T2D) or
type 1 diabetes (T1D) treated with insulin who have elevated LDL cholesterol levels despite
maximally tolerated statin therapy.
Methods: Participants at high cardiovascular risk with T2D (n = 441) or T1D (n = 76) and LDL
cholesterol levels ≥1.8 mmol/L (≥70 mg/dL) were randomized 2:1 to alirocumab:placebo
administered subcutaneously every 2 weeks, for 24 weeks' double-blind treatment.
Alirocumab-treated participants received 75 mg every 2 weeks, with blinded dose increase to
150 mg every 2 weeks at week 12 if week 8 LDL cholesterol levels were ≥1.8 mmol/L. Primary
endpoints were percentage change in calculated LDL cholesterol from baseline to week
24, and safety assessments.
Results: Alirocumab reduced LDL cholesterol from baseline to week 24 by a mean  standard
error of 49.0%  2.7% and 47.8%  6.5% vs placebo (both P < .0001) in participants with
T2D and T1D, respectively. Significant reductions were observed in non-HDL cholesterol
(P < .0001), apolipoprotein B (P < .0001) and lipoprotein (a) (P ≤ .0039). At week 24, 76.4%
and 70.2% of the alirocumab group achieved LDL cholesterol <1.8 mmol/L in the T2D and
T1D populations (P < .0001), respectively. Glycated haemoglobin and fasting plasma glucose
levels remained stable for the study duration. Treatment-emergent adverse events were
observed in 64.5% of alirocumab- vs 64.1% of placebo-treated individuals (overall population).
Conclusions: Alirocumab produced significant LDL cholesterol reductions in participants with
insulin-treated diabetes regardless of diabetes type, and was generally well tolerated. Concomi-
tant administration of alirocumab and insulin did not raise any safety concerns
(NCT02585778).
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1 | INTRODUCTION
Dyslipidaemia is a major risk factor for macrovascular complications
in both type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus
(T2D).1,2 In T2D, the development of dyslipidaemia, typically charac-
terized by elevated levels of non-HDL cholesterol and triglycerides
(TGs) and reduced levels of HDL cholesterol, is associated with insu-
lin resistance in most cases.3,4 By contrast, well-controlled individuals
with T1D can have a normal lipid profile, with lower TG and LDL cho-
lesterol levels and HDL cholesterol levels in the upper normal range
or even slightly elevated2,5; however, in the presence of poor glycae-
mic control, the profile of dyslipidaemia in individuals with T1D may
resemble that observed with T2D.4
Standard-of-care LDL cholesterol-lowering by statins, and in combi-
nation with ezetimibe, has been shown to lead to significant reductions in
cardiovascular events in individuals with diabetes.6–8 Current guidelines
generally recommend targeting an LDL cholesterol goal of <1.8 mmol/L
(<70 mg/dL), or even <1.3 mmol/L (<50 mg/dL), and/or a reduction of
≥50% from baseline in patients with T2D or T1D considered to be at high
or very high cardiovascular risk.5,9,10 Despite such strong recommenda-
tions, a significant proportion of individuals with diabetes do not reach
target LDL cholesterol levels in real-life studies,11–13 and are therefore
exposed to significant residual risk of cardiovascular events.
Alirocumab, a monoclonal antibody that binds to proprotein con-
vertase subtilisin/kexin type 9 (PCSK9), has been shown to have simi-
lar efficacy and safety in individuals with and without diabetes in
post hoc analyses.14–16 Some theoretical considerations have been
raised with regard to the use of PCSK9 inhibitors in individuals with
diabetes.17–19 Specifically, these include the safety of the concomi-
tant administration of 2 injectable agents (alirocumab, a monoclonal
antibody, and insulin, a biological agent). The potential for the effects
of alirocumab on glycaemic control and change in antidiabetic medi-
cation use, as well as immunogenicity in individuals with T2D and
T1D, also warrants further investigation.
The phase IIIb ODYSSEY DM-INSULIN study therefore sought to
characterize the efficacy and safety of alirocumab in insulin-treated
individuals with T1D or T2D at high cardiovascular risk not reaching
LDL cholesterol goals, despite maximum tolerated statin therapy, with
or without other lipid-lowering therapies (LLTs).
2 | MATERIALS AND METHODS
2.1 | Study design
ODYSSEY DM-INSULIN was a phase IIIb, randomized, double-blind,
placebo-controlled, parallel-group, multicentre trial, conducted at
103 sites in 10 countries (Austria, Belgium, France, Germany, Italy,
the Netherlands, Spain, Switzerland, the UK, and the USA) and
designed to evaluate the efficacy and safety of alirocumab in insulin-
treated people with hypercholesterolaemia and at high cardiovascular
risk (a complete list of study sites and investigators is available in the
Supporting Information, Text S1). Trial design and rationale have been
published previously.20
The study was conducted in accordance with the Declaration of
Helsinki and the International Conference on Harmonization Guide-
lines for Good Clinical Practice. The institutional review board or
independent ethics committee at each study centre approved the
study protocol, and written informed consent was obtained from
each participant. The trial was registered with clinicaltrials.gov
(Clinical trial reg. no. NCT02585778).
2.2 | Study population
The study population comprised people with insulin-treated T2D or
T1D and established atherosclerotic cardiovascular disease and/or at
least 1 additional cardiovascular risk factor, who had LDL cholesterol
levels ≥1.8 mmol/L (≥70 mg/dL) despite stable maximally tolerated
doses of statin with or without other LLTs. Individuals with statin
intolerance (therefore not taking statins) were also eligible for study
enrolment. Detailed inclusion and exclusion criteria are available in
the Supporting Information, Text S2.
2.3 | Study procedures
Briefly, the study consisted of a screening period of up to 3 weeks
and a double-blind treatment period of 24 weeks, followed by a
safety observation period of 8 weeks. Participants were on a stable
diet for glucose and lipid management, and received treatment for
diabetes in accordance with local/regional standards of care.
Eligible participants were randomized to alirocumab or placebo
(2:1, respectively), administered subcutaneously as a 1-mL solution
every 2 weeks via a prefilled pen device, with stratification by diabe-
tes type. Alirocumab was administered at a starting dose of 75 mg
every 2 weeks, with blinded dose increase to 150 mg every 2 weeks
(also 1 mL) at week 12 if week 8 LDL cholesterol levels were
≥1.8 mmol/L (≥70 mg/dL). Statins and other LLTs remained stable
throughout the entire duration of the study.
2.4 | Endpoints and assessments
The primary efficacy endpoint was the percent change in calculated
LDL cholesterol from baseline to week 24. Primary safety endpoints
were assessed (up to week 32) through treatment-emergent adverse
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event (TEAE) reports, laboratory data, product complaints, and vital
signs (including height, weight, blood pressure and heart rate).
Adverse events (AEs) of special interest, prespecified in the study
protocol, are detailed in the Supporting Information, Text S3. Treat-
ment acceptability was assessed in participants who self-injected,
using a 22-item validated patient-reported Injection-Treatment
Acceptance Questionnaire (I-TAQ).21 Anti-alirocumab antibodies
were measured at the time of randomization and at weeks 12 and
24.22 Persistent antidrug antibodies were defined as at least 2 consec-
utive post-baseline samples with positive antidrug antibodies sepa-
rated by at least a 12-week period. Neutralizing antidrug antibodies
are defined as those that inhibit labelled PCSK9:alirocumab binding in
an in vitro immunosorbent assay; however, this does not necessarily
translate to a clinical effect.22 A complete list of all endpoints and
assessments, as well as further details on study methods, is given in
the Supporting Information, Table S1 and Text S3.
2.5 | Statistical analysis
The primary efficacy endpoint was evaluated in the intention-to-treat
population; missing data were accounted for using a mixed effects
model with a repeated measures approach,23,24 using all available
post-baseline data within the analysis windows (weeks 8-24). Further
details on the determination of sample size and statistical analysis of
efficacy and safety endpoints are given in the Supporting Information,
Text S3.
3 | RESULTS
3.1 | Participants
In total, 441 participants with T2D and 76 with T1D were random-
ized 2:1 to receive alirocumab or placebo; of these, 469 (90.7%) com-
pleted the study on study treatment (Figure 1).
Baseline characteristics were generally well balanced between
the treatment groups for both the T2D and T1D populations
(Table 1). For those with T2D, imbalances in the alirocumab group
compared with the placebo group included a higher proportion of
participants receiving ezetimibe (15.3% vs 6.8%) and a higher propor-
tion receiving high-intensity statin (39.2% vs 27.4%). For those with
T1D, imbalances in the alirocumab group compared with the placebo
group included a higher proportion of participants receiving metfor-
min in addition to insulin (15.7% vs 0%) and a lower proportion of
men (56.9% vs 68.0%); in addition, mean calculated LDL cholesterol
was higher in the alirocumab group compared with the placebo group
(3.3 vs 2.9 mmol/L). The mean duration of study drug exposure was
23 weeks among those included in the safety analysis (344 partici-
pants in the alirocumab group and 170 participants in the placebo
group; Figure 1). Further baseline characteristics are detailed in
Table S2, Supporting Information. In addition, the reasons for taking a
lower statin dose than the maximum for participants on statin ther-
apy, and the reasons for not taking statin for those who are statin-
intolerant, are given in Table S3, Supporting Information. Overall, only
22.6% of participants randomized to alirocumab required a dose
increase from 75 to 150 mg every 2 weeks from week 12; this
included 20.2% of participants with T2D and 36.7% of those
with T1D.
3.2 | Primary efficacy endpoint in the overall
population
For the primary efficacy endpoint in the overall population, the least
squares (LS) mean (standard error [s.e.]) percentage change in calcu-
lated LDL cholesterol levels from baseline to week 24 was −50.1%
(1.9%) for alirocumab and −1.3% (2.4%) for placebo, with a difference
between groups of −48.8% (2.5%; P < .0001).
3.3 | Alirocumab efficacy in participants with T2D
For the primary efficacy endpoint in participants with T2D, the LS
mean (s.e.) percentage change in calculated LDL cholesterol levels
from baseline to week 24 was −48.2% (1.6%) for alirocumab and
+0.8% (2.2%) for placebo, with a difference between groups of
−49.0% (2.7%; P < .0001 [Table 2]). Subgroup analyses showed that
the efficacy of alirocumab was similar regardless of moderate chronic
kidney disease, age, duration of diabetes, baseline glycated haemoglo-
bin (HbA1c), history of atherosclerotic cardiovascular disease, and
other subgroups (Table S4, Supporting Information). LDL cholesterol
reductions in the alirocumab group were consistent from weeks 8 to
24 (Figure 2). Alirocumab resulted in significant reductions from base-
line to week 24 (difference vs placebo) in levels of non-HDL choles-
terol (−38.7%; P < .0001), apolipoprotein B (ApoB; −36.7%;
P < .0001), total cholesterol (−27.6%; P < .0001) and lipoprotein
(a) (Lp[a]; −18.4%; P < .0001), as well as a significant increase in HDL
cholesterol (difference vs placebo 4.4%; P < .01 [Table 2]). At week
24, the proportion of participants achieving LDL cholesterol
<1.8 mmol/L (<70 mg/dL) was 76.4% in the alirocumab group and
7.4% in the placebo group (P < .0001), and the proportion of individ-
uals attaining LDL cholesterol of <1.3 mmol/L (<50 mg/dL) was
50.7% in the alirocumab group and 2.7% in the placebo group
(P < .0001; Table S5, Supporting Information). In addition, 70.9% of
the alirocumab group and 13.8% of the placebo group attained non-
HDL cholesterol <2.6 mmol/L (<100 mg/dL; P < .0001 [Table S5,
Supporting Information]). Reductions from baseline to week 24 (differ-
ence vs placebo) in TG levels (−5.7%) were also observed, although
were not significant (P = .0902 [Table 2]). Reductions (difference vs
placebo) in LDL particle number (−40.2%; P < .0001) and LDL particle
size (−2.5%; P < .0001) at week 24 were observed, although signifi-
cance was nominal because of the hierarchical testing procedure used
(Table 2). Alirocumab resulted in reductions from baseline to week
24 (difference vs placebo) in apolipoprotein C-III (−10.0%) and TG-
rich lipoprotein cholesterol (−18.6% [Table S6, Supporting Informa-
tion]). The results of other efficacy endpoints are shown in Table S6,
Supporting Information.
3.4 | Alirocumab efficacy in participants with T1D
For the primary efficacy endpoint in participants with T1D, the LS
mean (s.e.) percentage change in LDL cholesterol concentrations from
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baseline to week 24 was −51.8% (3.7%) for alirocumab and −3.9%
(5.3%) for placebo, with a difference between groups of −47.8%
(6.5%; P < .0001 [Table 2]). Reductions in calculated LDL cholesterol
over time for both alirocumab and placebo groups are shown in
Figure 2. Although subgroup analyses were limited because of the
small size of the T1D population, results were consistent across sub-
groups (Table S7, Supporting Information). Alirocumab produced sig-
nificant reductions from baseline to week 24 (difference vs placebo)
in levels of non-HDL cholesterol (−42.7%), ApoB (−39.0%), total cho-
lesterol (−29.2%) and Lp(a) (−18.7%; all P values <.0001 except for
Lp[a] which was = .0039 [Table 2]). Alirocumab resulted in an
increase in HDL cholesterol (difference vs placebo 3.9%), although
this was not significant (P = .3434 [Table 2]). In addition, alirocumab
resulted in a decrease in TG levels (difference vs placebo −15.5%,
nominal P = .056). A reduction in LDL particle number (difference vs
placebo) from baseline to week 24 of −40.0% was also observed
(nominal P <.0001). Results of other efficacy endpoints were similar
to those described for the T2D population above (Tables S5 and S6,
Supporting Information).
3.5 | Diabetes-related endpoints
In the T2D population, the mean (standard deviation [s.d.]) absolute
change from baseline in HbA1c at week 24 was 0.2% (0.7%) (2.0
[8.1] mmol/mol) and 0.1% (0.7%) (0.7 [7.2] mmol/mol) in the alirocu-
mab and placebo groups, respectively. In the T1D population, mean
(s.d.) absolute change from baseline in HbA1c at week 24 was 0.0%
(0.6%) (−0.3 [6.6] mmol/mol) and −0.2% (0.4%) (−2.5 [4.0] mmol/mol)
in the alirocumab and placebo groups, respectively. The mean (s.d.)
absolute change in fasting plasma glucose (FPG) from baseline to
week 24 for the alirocumab and placebo groups was 9.5 (61.8) mg/dL
and 10.0 (47.0) mg/dL for the T2D population, respectively, and 9.5
(93.8) mg/dL and 14.6 (75.9) mg/dL for the T1D population. The
absolute values for HbA1c and FPG over time are shown in
Figures S1 and S2, Supporting Information. The total daily insulin
dose and number of antihyperglycaemic drugs did not change over
time in either the T2D or T1D population (Figures S3 and S4, Sup-
porting Information).
3.6 | Safety and tolerability
The proportion of participants with at least 1 TEAE was similar
between the alirocumab and placebo treatment groups, both for the
overall population combining T2D and T1D (64.5% vs 64.1%
[Table 3]), and for the separate T2D and T1D populations (66.9% vs
66.2% and 51.0% vs 52.0%, respectively [Table S8, Supporting Infor-
mation]). One death from myocardial infarction, occurring 1 month
after first administration of study treatment, was reported for an indi-
vidual with T2D in the placebo group. For the overall population,
treatment discontinuation because of a TEAE occurred in 17 partici-
pants (4.9%) in the alirocumab group and 4 participants (2.4%) in the
placebo group (Table 3). TEAEs leading to discontinuation (those with
more than 1 individual per treatment group at the preferred-term
level) were (alirocumab vs placebo group): headache (2 [0.6%] vs 0),
FIGURE 1 Participant flow diagram.
ADA, antidrug antibody; ITT, intention-
to-treat
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TABLE 1 Baseline characteristics (randomized population)
T2D T1D
Alirocumab
(n = 294)
Placebo
(n = 147)
Alirocumab
(n = 51)
Placebo
(n = 25)
Mean (s.d.) age, years 63.9 (8.9) 64.0 (9.4) 54.9 (10.1) 58.5 (7.8)
Age group, n (%)
<65 years 143 (48.6) 73 (49.7) 42 (82.4) 19 (76.0)
≥65 to <75 years 126 (42.9) 55 (37.4) 8 (15.7) 6 (24.0)
≥75 years 25 (8.5) 19 (12.9) 1 (2.0) 0
Male, n (%) 161 (54.8) 78 (53.1) 29 (56.9) 17 (68.0)
Race, n (%)
White 259 (88.1) 135 (91.8) 50 (98.0) 24 (96.0)
Black 27 (9.2) 7 (4.8) 1 (2.0) 0
Asian/Oriental 7 (2.4) 3 (2.0) 0 0
Other 1 (0.3) 2 (1.4) 0 1 (4.0)
Ethnicity, n (%)
Hispanic or Latino 13 (4.4) 8 (5.4) 1 (2.0) 0
Not Hispanic or Latino 280 (95.2) 138 (93.9) 50 (98.0) 25 (100)
Not reported/unknown 1 (0.3) 1 (0.7) 0 0
Mean (s.d.) BMI, kg/m2 32.6 (4.8) 32.7 (5.5) 30.6 (6.3) 28.7 (4.8)
Mean (s.d.) HbA1c, % 7.5 (1.0) 7.5 (1.0) 7.8 (1.0) 7.7 (0.8)
Mean (s.d.) HbA1c, mmol/mol 58.6 (10.5) 58.9 (11.1) 62.2 (10.3) 60.4 (8.5)
HbA1c <7% (<53 mmol/mol), n (%) 94 (32.0) 47 (32.0) 10 (19.6) 4 (16.0)
Mean (s.d.) FPG
mmol/L 8.5 (2.8) 8.5 (2.9) 9.6 (3.9) 9.2 (4.2)
mg/dL 153.6 (50.3) 152.6 (51.8) 172.8 (69.7) 166.5 (75.6)
ASCVD, n (%) 119 (40.5) 58 (39.5) 11 (21.6) 5 (20.0)
CHDa 102 (34.7) 51 (34.7) 9 (17.6) 3 (12.0)
No ASCVD + additional CV risk factors, n (%) 175 (59.5) 89 (60.5) 40 (78.4) 20 (80.0)
Micro-/macro-albuminuria, CKD and/or retinopathy 73 (41.7) 31 (34.8) 22 (55.0) 12 (60.0)
≥3 additional CV risk factorsb 102 (58.3) 45 (50.6) 17 (42.5) 10 (50.0)
Median (Q1:Q3) duration of diabetes, years 15.4 (10.9:21.5) 16.5 (12.0:21.5) 34.6 (22.3:43.6) 36.6 (27.6:43.4)
Median (Q1:Q3) duration of insulin use, years 5.6 (2.8:11.3) 6.6 (2.9:12.3) 34.6 (21.6:42.6) 36.6 (27.6:43.4)
Current smoker, n (%) 38 (12.9) 15 (10.2) 10 (19.6) 3 (12.0)
Mean (s.d.) systolic blood pressure, mm Hg 131.7 (16.1) 132.4 (15.5) 129.9 (14.5) 126.5 (15.5)
Mean (s.d.) diastolic blood pressure, mm Hg 76.0 (9.2) 75.1 (8.2) 74.7 (9.8) 69.5 (8.5)
Mean (s.d.) eGFR, mL/min/1.73 m2 74.0 (24.3) 76.4 (24.8) 83.9 (23.9) 74.6 (18.3)
CKDc, n (%) 62 (21.1) 25 (17.0) 6 (11.8) 4 (16.0)
Baseline lipids
Mean (s.d.) calculated LDL cholesterol
mmol/L 2.9 (0.9) 2.8 (1.0) 3.3 (1.5) 2.9 (0.8)
mg/dL 110.8 (36.5) 109.6 (39.1) 126.4 (58.2) 110.2 (31.2)
Mean (s.d.) measured LDL cholesterol
mmol/L 2.9 (0.9) 2.9 (1.0) 3.3 (1.5) 2.8 (0.8)
mg/dL 112.1 (34.3) 110.5 (37.4) 127.7 (58.1) 109.8 (31.4)
Mean (s.d.) ApoB, mg/dL 97.0 (24.7) 96.2 (26.8) 99.7 (35.6) 87.0 (21.0)
Mean (s.d.) non-HDL cholesterol
mmol/L 3.7 (1.1) 3.8 (1.3) 3.9 (1.6) 3.4 (0.9)
mg/dL 144.7 (42.6) 144.9 (48.5) 150.2 (62.9) 130.7 (34.2)
Total cholesterol
mmol/L 4.9 (1.1) 4.9 (1.2) 5.3 (1.7) 5.1 (0.9)
mg/dL 190.2 (42.4) 189.9 (47.6) 205.1 (65.1) 195.2 (36.0)
(Continues)
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TABLE 1 (Continued)
T2D T1D
Alirocumab
(n = 294)
Placebo
(n = 147)
Alirocumab
(n = 51)
Placebo
(n = 25)
Median (Q1:Q3) TGs
mmol/L 1.7 (1.2:2.3) 1.7 (1.2:2.6) 1.2 (0.9:1.5) 1.1 (0.8:1.5)
mg/dL 146.0 (108.0:205.0) 153.0 (105.0:231.0) 105.0 (79.0:136.0) 99.0 (66.0:130.0)
Mean (s.d.) HDL cholesterol
mmol/L 1.2 (0.3) 1.2 (0.3) 1.4 (0.4) 1.7 (0.5)
mg/dL 45.5 (12.5) 44.9 (13.2) 54.9 (13.7) 64.4 (17.4)
Median (Q1:Q3) Lp(a), mg/dL 16.0 (5.0:55.0) 14.0 (5.0:38.0) 17.0 (6.0:28.0) 12.0 (4.0:37.0)
Mean (s.d.) ApoC-III, mg/dL 11.2 (4.5) 11.4 (4.9) 8.9 (3.6) 8.8 (2.6)
Median (Q1:Q3) TG-rich lipoprotein cholesterol
mmol/L 0.8 (0.5:1.0) 0.7 (0.5:1.1) 0.5 (0.4:0.7) 0.6 (0.4:0.7)
mg/dL 29.0 (21.0:40.0) 29.0 (19.0:41.0) 21.0 (15.0:29.0) 21.0 (15.0:26.0)
Mean (s.d.) LDL particle number, nmol/L 1355.5 (391.6) 1373.0 (414.0) 1383.4 (589.5) 1104.2 (385.8)
Mean (s.d.) LDL particle size, nm 20.6 (0.6) 20.5 (0.6) 21.0 (0.7) 21.0 (0.5)
Mean (s.d.) free PCSK9, ng/mL 251.1 (85.4) 251.4 (87.1) 212.1 (62.6) 202.3 (83.0)
Mean (s.d.) total PCSK9, ng/mL 532.1 (163.9) 516.4 (156.3) 523.6 (133.0) 485.4 (180.1)
Concomitant lipid-lowering therapy, n (%)
Any statin 222 (75.5) 113 (76.9) 36 (70.6) 16 (64.0)
Statin intensityd,e
Highf 87 (39.2) 31 (27.4) 15 (41.7) 7 (43.8)
Moderatef 123 (55.4) 77 (68.1) 20 (55.6) 8 (50.0)
Lowf 11 (5.0) 3 (2.7) 1 (2.8) 1 (6.3)
Statin monotherapy 174 (59.2) 88 (59.9) 31 (60.8) 12 (48.0)
Any other LLTs (other than statin) 78 (26.5) 33 (22.4) 7 (13.7) 7 (28.0)
Cholesterol absorption inhibitor (ezetimibe) 45 (15.3) 10 (6.8) 2 (3.9) 3 (12.0)
Statin intoleranceg, n (%) 72 (24.5) 33 (22.4)h 15 (29.4) 9 (36.0)
Concomitant antihyperglycaemic drugs, n (%)
Insulin 293 (99.7)i 146 (99.3)i 51 (100.0) 25 (100.0)
Any other antihyperglycaemic drugs 202 (68.7) 110 (74.8) 8 (15.7) 1 (4.0)
Biguanides (metformin) 172 (58.5) 83 (56.5) 8 (15.7) 0
Median (Q1:Q3) total daily insulin dosej
IU 51.5 (31.4:80.0) 49.5 (30.0:80.0) 62.9 (44.1:85.0) 48.6 (32.4:69.1)
IU/kg 0.6 (0.4:0.9) 0.6 (0.3:0.8) 0.7 (0.6:0.9) 0.5 (0.5:0.7)
Abbreviations: Apo-CIII, apolipoprotein C-III; ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; CHD, coronary heart disease; CKD,
chronic kidney disease; CV, cardiovascular; eGFR, estimated glomerular filtration rate.
a CHD defined as history of acute myocardial infarction, silent myocardial infarction, unstable angina, coronary revascularization procedure, or clinically
significant CHD diagnosed by invasive or non-invasive testing.
b CV risk factors (in addition to diabetes and hypercholesterolaemia) included hypertension, current smoker, age ≥45 years (men) or ≥55 years (women),
history of micro-/macroalbuminuria or diabetic retinopathy, family history of premature CHD, low levels of HDL cholesterol, or documented CKD.
c Defined as eGFR ≥15 to <60 mL/min/1.73 m2.
d For patients who are currently taking statin.
e High-intensity statin: atorvastatin 40 to 80 mg, rosuvastatin 20 to 40 mg, or simvastatin 80 mg daily. Moderate-intensity statin: atorvastatin 10 to
20 mg, rosuvastatin 5 to 10 mg, simvastatin 20 to 40 mg, pravastatin 40 to 80 mg, lovastatin 40 mg, fluvastatin 80 mg, or pitvastatin 2 to 4 mg daily.
Low-intensity statin: simvastatin 10 mg, pravastatin 10 to 20 mg, lovastatin 20 mg, fluvastatin 20 to 40 mg, or pitavastatin 1 mg daily. Participants
receiving more than one intensity of statin were counted in the highest intensity level.
f Percentage of patients receiving any statin.
g Number of participants not currently taking statin who are statin-intolerant based on medical history, as reported by investigator.
h One participant was not receiving statin therapy at randomization, but not classified as statin-intolerant based on medical history.
i One participant in the alirocumab group and one participant in the placebo group were not receiving insulin at the time of randomization, and they
remained without insulin treatment for the duration of the trial.
j Intention-to-treat population.
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cognitive disorder (2 [0.6%] vs 0), allergic dermatitis (2 [0.6%] vs 0)
and myalgia (3 [0.9%] vs 2 [1.2%]; Table S9, Supporting Information).
There were no reported cases of local injection site reactions meeting
the predefined AEs of special interest criteria (ie, those allergic in
nature requiring consultation) in either the T2D or T1D population
(Table 3 and Table S8, Supporting Information). Local injection-site
reaction TEAEs were reported in 5 participants (1.7%) in the alirocu-
mab group vs 5 participants (3.4%) in the placebo group for the T2D
population; the occurrence in the T1D population was 2 participants
(3.9%) vs 3 participants (12.0%), respectively. Most of the local
injection-site reactions were mild in intensity, with only 2 occurrences
(1 each in the alirocumab and placebo group) of a moderate intensity.
Other predefined AEs of special interest are shown in Table 3.
For the T2D population, 3.2% of alirocumab and 0% of placebo-
treated participants had treatment-emergent persistent antidrug
antibodies with a low titre; for the T1D population, 2.1% of alirocumab-
and 0% of placebo-treated participants had treatment-emergent
persistent antidrug antibodies with a low titre. The proportion of
participants in the alirocumab group at weeks 12 and 24 with
neutralizing antidrug antibodies was 2.1% and 0.7% for the T2D popula-
tion, and 0% and 2% for the T1D population, respectively. No neutraliz-
ing antidrug antibodies were observed in the placebo group.
3.7 | Treatment acceptability
Participant-reported acceptability of subcutaneous injection of study
treatment was high (including high acceptance of treatment-related
side effects) and showed no significant difference between treatment
arms in perceived efficacy, acceptance of side effects, injection self-
efficacy (confidence in self-injection), injection convenience, or over-
all acceptance for either the T2D or T1D population (Table S10, Sup-
porting Information).
4 | DISCUSSION
This was the first trial with a PCSK9 inhibitor that specifically ran-
domized individuals with insulin-treated diabetes. Subanalyses in
FIGURE 2 Percent change from
baseline in LDL cholesterol over time
per treatment randomization. A,
Participants with T2D. B, Participants
with T1D (intention-to-treat analysis)
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individuals with diabetes have previously been reported for PCSK9
inhibitors14,16,25; however, conclusions of those analyses were limited
because of the non-randomized nature of the subgroups that were
assessed. In addition, in previous alirocumab ODYSSEY phase III tri-
als, only a minority of participants with diabetes were receiving insu-
lin, and very few had T1D.20 In the present study, where 40.1% of
participants with T2D also had atherosclerotic cardiovascular disease
and remaining participants had additional cardiovascular risk factors,
the population of this study represents a group with very high risk of
future cardiovascular events,2,26 who had uncontrolled LDL choles-
terol despite receiving maximally tolerated statin.
Alirocumab was shown to be superior in reducing LDL cholesterol
levels vs placebo in insulin-treated individuals with T2D or T1D at high
cardiovascular risk. The magnitude of LDL cholesterol reduction at week
24 (49.0% and 47.8% vs placebo for the T2D and T1D populations,
respectively) was consistent with that seen in previous ODYSSEY phase
III studies with participants on background statin therapy. For example, a
pooled analysis of the overall population of 8 ODYSSEY phase III trials
showed that alirocumab reduced LDL cholesterol by 48.9% (vs 19.3%
reduction for ezetimibe) and 48.6% (vs 4.2% increase for placebo) from
baseline to week 24.27 In addition, a subanalysis of ODYSSEY COMBO II
showed that alirocumab reduced LDL cholesterol by 49.1% (vs 18.4%
reduction for ezetimibe) in participants with diabetes and by 51.2%
(vs 21.8% reduction for ezetimibe) for participants without diabetes.16
A pooled analysis of 6 ODYSSEY phase III trials showed that an
alirocumab dose increase to 150 mg every 2 weeks at week 12 was
more likely in participants with higher baseline LDL cholesterol levels;
the best single predictor of dose increase was a baseline LDL choles-
terol level further from the prespecified goal of LDL cholesterol
<1.8 mmol/L (<70 mg/dL).28 This could explain the observation in
the present study that a greater proportion of alirocumab-treated
individuals with T1D required dose increase at week 12 compared
with those with T2D, as the T1D group had a higher baseline LDL
cholesterol level (126.4 mg/dL [3.3 mmol/L]) compared with the T2D
group (110.8 mg/dL [2.9 mmol/L]).
A moderate reduction in TGs was observed with alirocumab
treatment in both the T2D and T1D populations (small reductions
also seen in previous trials),27 suggesting that inhibiting extracellular
PCSK9 has a minor impact, if any, in the metabolism of TGs.
As statins have been found to be associated with an increased
risk of diabetes,29–31 and because of reports linking PCSK9 to glucose
homeostasis,17–19,32,33 there is an interest in the effect of PCSK9
inhibitors on measures of glycaemic control. Consistent with recent
pooled analyses of 10 ODYSSEY phase III studies34 and 14 ODYSSEY
phase II and III studies,15 which showed no effect of alirocumab on
glycaemia in people with or without diabetes, in the present trial,
changes in HbA1c and FPG levels were minimal in individuals with
either T2D or T1D receiving insulin treatment for the 24-week dura-
tion of the trial. Importantly, the total daily insulin dose and number
of other antihyperglycaemic drugs were also unchanged for the dura-
tion of the study, providing further evidence that alirocumab did not
affect glycaemic control. A lack of effect on glycaemic control has
also been observed with another PCSK9 inhibitor35; however, the
effect of PCSK9 inhibitors on glycaemic control in studies of longer
duration (>2 years) needs to be studied.
TABLE 3 Summary of TEAEs for overall population (safety
population)
% (n) of participantsa
Alirocumab
(n = 344)
Placebo
(n = 170)
TEAEs
Any TEAE 64.5 (222) 64.1 (109)
Treatment-emergent SAE 9.0 (31) 9.4 (16)
TEAEs leading to death 0 0.6 (1)
TEAEs leading to treatment
discontinuation
4.9 (17) 2.4 (4)
AEs of special interest
Allergic events requiring
consultation with another
physician
1.5 (5) 2.4 (4)
Local injection-site reactions
that are allergic in nature
and require consultation
with another physician
0 0
Pregnancy of female
participant/partner of male
participant
0 0
Symptomatic overdose
(accidental or intentional)
with study treatment
0 0
Neurological events requiring
additional examination/
procedures and/or
consultation with a
specialist
0.3 (1) 0.6 (1)
Neurocognitive events 1.2 (4) 0
Increase in alanine
aminotransferase
0.6 (2) 0.6 (1)
TEAEs occurring in ≥2% of participants (in any group)
Bronchitis 2.6 (9) 0.6 (1)
Pneumonia 0.6 (2) 2.4 (4)
Nasopharyngitis 4.9 (17) 5.3 (9)
Upper respiratory tract
infection
0.9 (3) 2.4 (4)
Urinary tract infection 4.4 (15) 4.1 (7)
Influenza 2.3 (8) 2.9 (5)
Hyperglycaemia 0.9 (3) 2.4 (4)
Hypoglycaemia 1.7 (6) 2.4 (4)
Headache 2.9 (10) 2.4 (4)
Dizziness 2.6 (9) 1.2 (2)
Hypertension 2.9 (10) 2.9 (5)
Cough 1.5 (5) 2.9 (5)
Diarrhoea 4.4 (15) 4.1 (7)
Nausea 2.3 (8) 2.4 (4)
Arthralgia 2.9 (10) 1.8 (3)
Myalgia 4.4 (15) 1.8 (3)
Musculoskeletal pain 1.2 (4) 2.4 (4)
Pain in extremity 1.7 (6) 2.9 (5)
Fatigue 2.0 (7) 1.8 (3)
Oedema peripheral 2.0 (7) 0.6 (1)
Fall 2.0 (7) 1.8 (3)
Abbreviations: TEAE, treatment-emergent adverse event; SAE, serious
adverse event.
a Participants may be counted in more than one category.
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A previous study suggested that PCSK9 may have a reduced role
in ApoB catabolism in those with poorly controlled T2D (HbA1c
>7%); the negative correlation between plasma PCSK9 and the frac-
tional catabolic rate of LDL-ApoB observed in the non-diabetic group
(R = −0.61, P = .002) was only observed in the T2D population in
those with HbA1c ≤7% (R = −0.70, P = .08).36 In the present study,
subgroup analyses showed an apparent reduction in placebo-
corrected LDL cholesterol percentage reduction in the T2D popula-
tion with baseline HbA1c ≥9% vs lower HbA1c baseline values
(Table S4, Supporting Information); however, this was attributable to
an LDL cholesterol reduction of 13.2% observed in the placebo group
with HbA1c ≥9%, whereas LDL cholesterol reductions were similar
across baseline HbA1c levels in the alirocumab group.
In the present study, alirocumab was well tolerated, with similar
proportions of participants with at least 1 TEAE in the alirocumab
and placebo groups. In previous alirocumab trials, the frequency of
injection-site reactions in the overall patient population was generally
found to be higher with alirocumab vs placebo or ezetimibe con-
trols.37 In the present trial, in participants with T2D or T1D, the over-
all incidence of local injection-site reactions was low relative to
previous studies, with no greater incidence in the alirocumab group
relative to placebo; these reactions were generally mild in nature.
Previous subgroup analyses have shown that individuals with diabe-
tes tend to have fewer injection-site reactions than those without
diabetes.15,16 A higher proportion of participants discontinued treat-
ment with alirocumab because of an AE compared with the placebo
group; however, no pattern emerged when analysed at the preferred-
term level. The incidence of neurocognitive AEs (1.4% of alirocumab-
treated participants only in the T2D population) was similar to that
shown in results from a pooled analysis of 14 phase II and III trials,
which reported an incidence of 0.9% in the alirocumab group of the
placebo-controlled pool.37 The frequencies of treatment-emergent
persistent antidrug antibodies and neutralizing antibodies were similar
to those reported previously from a pooled analysis of 10 phase III
alirocumab trials, which demonstrated LDL cholesterol reductions
that were maintained for the duration of the trials, regardless of anti-
drug antibody status.22
Uniquely for a PCSK9 inhibitor, we assessed participant acceptance
of study drug injections using the validated I-TAQ survey.21 Results of
this survey indicated that participants were confident in their ability to
inject themselves, that there were high levels of acceptance for the
injectable study drug, and that there was no difference between treat-
ment arms in the perceived frequency of side effects. These results are
consistent with an early study investigating patient perspectives of pos-
sible injection devices for alirocumab administration.38
Limitations of this analysis include the relatively short treatment
period for the assessment of potential interactions between alirocu-
mab and insulin treatment and of any potential long-term effects of
alirocumab on glycaemic control. The proportion of participants with
statin intolerance was higher than generally reported. This, although
not a limitation per se, may be a consequence of inclusion criteria
detailed above favouring preferential selection of participants with
suboptimal statin use, and thereby statin intolerance.
In summary, the present study showed the feasibility of concomi-
tant therapy with alirocumab and insulin, and showed that alirocumab
produced significant LDL cholesterol reductions in individuals with
both T2D and T1D receiving insulin treatment who were at high car-
diovascular risk with hypercholesterolaemia, with no apparent effect
on overall safety or measures of glycaemic control. Clinical cardiovas-
cular events with alirocumab are assessed in the ongoing ODYSSEY
OUTCOMES study (NCT01663402; ~18 000 individuals) that
includes a subgroup analysis in the significant number of the trial
population with diabetes.39 The effect of another PCSK9 inhibitor
(evolocumab) was investigated in the FOURIER clinical outcomes
study; a prespecified subanalysis in participants with diabetes has
been recently reported.40
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